Promomed Group presented the principles of corporate social responsibility policy at the BIOTECHMED conference in Gelendzhik

Promomed Group presented the principles of corporate social responsibility policy at the business breakfast "CSR - an attribute of modern business?", held on the second day of the BIOTECHMED conference in Gelendzhik.

Promomed Group builds a sustainable development program, including a corporate social responsibility unit, based on the interests and expectations of the medical community, its patients, as well as employees, their families, and all residents of the manufacturing region. The Company is guided in this activity by the UN Sustainable Development Goals: health and well-being; affordable education; decent work.

"We work for patients, work closely with the medical community, and live in a society. It is logical that Promomed's humanitarian and social activities are directed here. Being a pharmaceutical company and developing modern medicines is already a socially oriented business in itself, but the company does not limit itself to this," she notedEkaterina Kumanina, Director of Corporate Communications, Promomed Group.

Over the past year, the group's most prominent CSR programs have been promotions:

Areplivir for Doctors is a gratuitous provision of direct-acting antiviral agent to medical specialists working in "red zones";

a system of educational, educational and scientific events aimed at combating obesity and restoring metabolism;
a set of programs on the territory of the Republic of Mordovia: the opening of the scientific and educational laboratory for the synthesis of active pharmaceutical substances at the Ogarev Moscow State University, the launch of "industrial tourism" routes at the Biochemist plant in Saransk, the organization of open lectures by leading scientists and experts for University students and anyone interested in science. "We will continue to develop our systemic activity, for us it is a long-term activity that is inextricably linked to the future of the company," Ekaterina Kumanina is convinced.